Effetti dell'Integrazione di Akkermansia Muciniphila e Berberina sulla Sensibilità all'Insulina nei Lavoratori Turnisti (Shift2Health)
Effetti dell'Integrazione di Akkermansia Muciniphila e Berberina sulla Sensibilità all'Insulina nei Lavoratori Turnisti: uno Studio in Doppio Cieco, Randomizzato, Controllato con Placebo, Crossover all'interno del Progetto Shift2Health
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.
Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.
Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.
Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.
The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.
These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Miriam Ressler, PhD
- Numero di telefono: +4331654536677
- Email: miriam.ressler@fh-joanneum.at
Luoghi di studio
-
-
Styria
-
Graz, Styria, Austria, 8020
- Reclutamento
- FH JOANNEUM University of Applied Sciences
-
Contatto:
- Miriam Ressler, PhD
- Numero di telefono: +4331654536677
- Email: miriam.ressler@fh-joanneum.at
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Health care or industrial shift worker
- Employed or self-employed working ≥ 24 h/week
- Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
- Night shift work duration > 3 years
- 4 or more night shifts/month
Exclusion Criteria:
- BMI of 40 kg/m² or higher
- Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
- Bariatric surgery
- Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
- Diagnosed diabetes type 1 or type 2
- Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
- Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
- Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
- Regular intake of anticoagulants
- Known allergy to any inactive or active ingredients in the study products
- Participation in other clinical intervention trials during the study
- Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: AB Group
Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
|
Sperimentale: BA Group
Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in gut microbiom composition between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in FABPi between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of FABP intestinal (FABPi) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in zonulin between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of zonulin in blood (ng/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in LPB between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in CRP between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood pressure between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Systolic BP (mmHG) and diastolic BP (mmHG) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in melatonin between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
6-sulfatoxymelatonin in urine (µg/L) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in BMI between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Body mass index (BMI) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in body composition between the baseline and endpoint change in the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Bioelectrical Impedance Analysis (BIA) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in metabolomics at the end of the two periods
Lasso di tempo: At the beginning and the end of each intervention period (week 12, week 28)
|
Metabolomic profiles obtained with LC-MS/MS |
At the beginning and the end of each intervention period (week 12, week 28)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie del sistema nervoso
- Disturbi della nutrizione
- Malattie metaboliche
- Ipernutrizione
- Peso corporeo
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Iperinsulinismo
- Iperglicemia
- Condizioni patologiche, segni e sintomi
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Sovrappeso
- Obesità
- Resistenza all'insulina
- Stato prediabetico
- Intolleranza al glucosio
- Disturbi cronobiologici
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 1306/2025
- 101080788 (Altro numero di sovvenzione/finanziamento: Horizon Europe)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .